NCT06216782 Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
| NCT ID | NCT06216782 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2023-12-16 |
| Primary Completion | 2033-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2023-12-16 with a primary completion date of 2033-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc. Although the growth and spread of the tumor can be controlled to a certain extent, the cure rate for patients with progressive stage is still low and the prognosis is poor. Neoadjuvant therapy intends to use chemotherapy, immunotherapy, and targeted therapy to reduce the size and load of the tumor before surgery, to improve the surgical resection rate and therapeutic effect. 1. Primary research objective: to explore the therapeutic efficacy of patients with different characteristics under different neoadjuvant therapeutic regimens. 2. Secondary objectives To investigate the strengths and weaknesses of different neoadjuvant regimens in real-world clinical practice, and to investigate the long-term outcomes of patients treated with different regimens.
Eligibility Criteria
Inclusion Criteria: 1. Age greater than or equal to 18 years; 2. Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer; 3. Received neoadjuvant therapy after diagnosis; 4. Written informed consent. Exclusion Criteria: 1. Patients enrolled in other clinical trials; 2. Patients refused enrollment in this study; 3. Patients refused follow-up.
Contact & Investigator
Peng Zhang, Ph.D.
PRINCIPAL INVESTIGATOR
Shanghai Pulmonary Hospital, Shanghai, China
Frequently Asked Questions
Who can join the NCT06216782 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06216782 currently recruiting?
Yes, NCT06216782 is actively recruiting participants. Contact the research team at zhangpeng1121@tongji.edu.cn for enrollment information.
Where is the NCT06216782 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06216782 clinical trial?
NCT06216782 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China. The principal investigator is Peng Zhang, Ph.D. at Shanghai Pulmonary Hospital, Shanghai, China. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.